Documentation Red Flags
A manufacturer unwilling or unable to provide a genuine, batch-specific certificate of analysis before purchase, or one that provides only generic specification sheets rather than actual test data, should raise immediate concern. Similarly, certificates that appear inconsistent in formatting, contain unexplained gaps, or show suspiciously round numbers across multiple parameters are worth scrutinizing closely, since genuine analytical data typically shows natural variation rather than uniformly clean figures.
Requests for certification numbers that cannot be verified through the relevant issuing body’s registry, or certification claims for standards that don’t clearly apply to the manufacturer’s stated product line, are worth following up on directly before proceeding further.
Communication and Transparency Red Flags
Evasiveness about the actual manufacturing location, an inability or refusal to arrange any form of facility verification, or inconsistent answers to the same technical question asked at different points in the sales process are all signals worth taking seriously. Legitimate manufacturers, even smaller ones without extensive marketing infrastructure, are generally willing to have direct technical conversations and provide consistent, specific answers about their process and facility.
Pressure to commit to a purchase quickly, particularly combined with reluctance to provide documentation first, runs counter to how established manufacturers typically operate and is worth treating as a caution signal rather than simply a different sales style.
Pricing That Doesn’t Match Quality Claims
Pricing significantly below the range quoted by several comparable manufacturers for the same specification and grade should prompt closer scrutiny rather than being treated simply as a good deal, since achieving genuine GMP-grade quality and documentation carries real costs that are reflected in legitimate manufacturer pricing. This doesn’t mean the lowest-priced option is automatically problematic, but it does mean the documentation and verification steps described elsewhere in this series become more, not less, important when a price appears unusually favorable.
Buyers should be particularly cautious of pharmaceutical-grade claims paired with pricing closer to typical research-grade rates, since the cost structure required to genuinely support pharmaceutical-grade documentation and quality systems does not disappear simply because a manufacturer offers a lower price.
What to Do When You Spot a Red Flag
A single minor inconsistency does not automatically disqualify a manufacturer, but it warrants direct follow-up and should factor into the broader evaluation rather than being dismissed. Multiple red flags across different categories, particularly when combined with reluctance to address direct follow-up questions, are a stronger signal that the manufacturer relationship carries elevated risk.
For any application with regulatory, safety, or significant financial consequences, treating red flags as a reason to expand due diligence, potentially including a formal audit as described elsewhere in this series, is a more appropriate response than either ignoring the concern or immediately eliminating the candidate without further investigation.